CHOSOURCE™ CHO-K1 ADCC+ cell line

Engineered for increased therapeutic antibody efficacy

Horizon's newest CHOSOURCE cell line eliminates the cell’s natural fucosylation activity to increase therapeutic antibody efficacy and potency. Elimination of core fucose on the Fc N-glycan of antibodies enhances antibody-dependent cellular cytotoxicity (ADCC) activity of immune effector cells by increasing antibody binding to the FcgRIIIa receptor present on effector cells.

 

Afucosylated antibody benefits:

  • Increase therapeutic efficacy of antibodies for use in oncology, infectious and autoimmune diseases
  • Improve drug potency, expand the therapeutic window and reduce dosage requirements
  • Reduce dosage requirements and undesirable side effects of your therapeutic antibody treatments

 

Why use CHOSOURCE CHO-K1 ADCC+ cell line from Horizon?

  • Proven track record with existing CHOSOURCE CHO-K1 GS KO cell line
  • Over 100+ licenses and multiple regulatory filings worldwide
  • Adaptable platform - can be successfully used with:
    • Various vector systems
    • Multiple media and processes
  • Non-royalty bearing with no license tie-ins to specific vendors, technologies, or service providers

Contact us to discuss your project


Required fields marked with * Required


 

Learn more about CHOSOURCE

 

Download asset 

DOWNLOAD PRODUCT BROCHURE

CHO-K1 GS KO Expression Platform

Streamline your manufacturing process and improve production to accelerate your biotherapeutic pipeline

 

 
Play video

VIEW WEBINAR

Redesigning CHO: A new frontier in bioprocessing
See how Horizon is engineering improved CHO expression hosts for both research and commercial use to suit specific needs during discovery, development, and protein production.
CHOSOURCE™ CHO-K1 ADCC+ cell line

NEW POSTER - CHOSOURCE CHO-K1 ADCC+ Cell Line

Discover how the CHOSOURCE CHO-K1 ADCC+ cell line increases Antibody Dependent Cellular Cytotoxicity (ADCC) making it a valuable tool in the production of biotherapeutics for Oncology, Anti-infectives and Auto-immune diseases.